Sulfonylurea Response in Patients With Diabetes Due to Kir6.2 Mutations
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate whether patients with diabetes due to Kir6.2
mutations can be treated with sulfonylurea medication rather than insulin, and if this is the
case to investigate the mechanism for sulfonylurea response.
Phase:
N/A
Details
Lead Sponsor:
Royal Devon and Exeter NHS Foundation Trust
Collaborators:
Haukeland University Hospital Hôpital Necker-Enfants Malades Wellcome Trust